Regenxbio's RGX-121 gene therapy for Hunter syndrome is the main catalyst, with FDA approval targeted for February 2026. Recent clinical data shows RGX-121 can address neurological decline, a major ...
Hosted on MSN
Three-Year-Old Boy With Rare Hunter Syndrome Makes History As Breakthrough Gene Therapy Halts His Disorder
A three-year-old boy from California has stunned doctors with his rapid progress after receiving a world-first gene therapy for Hunter syndrome, a rare inherited condition that causes progressive ...
Hosted on MSN
2 SC boys find hope in new treatment and each other
GREENVILLE, S.C. - Two Greenville families are navigating one of the rarest diagnoses a parent can receive — and they are doing it together. Both families learned their sons had Hunter syndrome, a ...
The last time I spoke about Regenxbio (RGNX) it was with respect to a Seeking Alpha article entitled "Regenxbio :Wet AMD ABBV-RGX-314 Results Remain On Track For 2026". In this particular article, I ...
A breakthrough drug treating a rare genetic disorder is giving families new hope. Roran Jaskulski, 6, is among the first in the country to receive the treatment AVLAYAH. Children's Wisconsin is the ...
MILWAUKEE - A breakthrough drug that treats a rare disorder is giving families new hope, and Children's Wisconsin is playing a key role. For the last few months, 6-year-old Roran Jaskulski has spent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results